News
Public · Published
Cipla: Nomura maintains 'Buy' with Rs 1,510 target ahead of Q2 results
Nomura maintained a 'Buy' rating on Cipla with a target price of Rs 1,510 ahead of Q2 results. It expects steady September-quarter growth and an EBITDA margin recovery to 19.2% from 16.7%, supported by partnerships, acquisitions and in-licensing deals in the One-India business.
Published:
Updated:
What happened
Nomura maintained a 'Buy' rating on Cipla with a target price of Rs 1,510 ahead of Q2 results. It expects steady September-quarter growth and an EBITDA margin recovery to 19.2% from 16.7%, supported by partnerships, acquisitions and in-licensing deals in the One-India business.
Confirmed
Global impact / market context
A higher profit per sale means Cipla keeps more from each rupee of revenue, which can lift earnings even if sales grow only modestly. The note also flags that respiratory and anti-infective therapies, nearly half of branded formulation revenue, remain weak, so growth depends on newer deals.
Analyst inference
Investors weighing Cipla against peers are being told its India growth comes mainly from partnerships and acquisitions rather than existing core therapies. That mix shifts the risk: deal-led growth can scale quickly but depends on continued licensing and distribution arrangements, while subdued core segments may cap overall momentum.
Analyst inference
What to watch
- Nomura expects Cipla's One-India segment to grow low- to mid-teen year-on-year, with tirzepatide licensing, the Pfizer brands distribution agreement and the Inzepra acquisition adding around 600 basis points to growth, which means percentage points of extra growth. Confirmed
- Watch whether the projected EBITDA margin of 19.2% actually appears, which means the share of revenue left after operating costs. Missing it would weaken the case for the target price and suggest cost pressures. Analyst inference
- Track whether Cipla's respiratory and anti-infective therapies, nearly half of branded formulation revenue, recover from single-digit growth; without that, deal-driven gains must carry more of the total. Proposed
Evidence
- Original source link unavailable